All In Biotech

Drug Trial Radar · NCT06466135

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jul 2, 2024

Primary completion

Mar 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Walden BiosciencesIndustry
Sponsor type
Industry
First posted
Jun 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy \[PMN\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.

Conditions

  • Diabetic Nephropathies
  • Primary Focal Segmental Glomerulosclerosis
  • Minimal Change Disease
  • Primary Immunoglobulin A Nephropathy
  • Primary Membranous Nephropathy

Interventions

  • WAL0921Drug

    Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.

  • PlaceboDrug

    Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse eventsTime frame: Baseline to Week 36

Locations

50 sites in 7 countries. Site status is shown where the registry gives one.

  • Academic Medical Research Institute

    Los Angeles, California · Recruiting

  • Colorado Kidney and Vascular Care

    Denver, Colorado · Recruiting

  • D & H Tamarac Research Center

    Tamarac, Florida · Recruiting

  • Fides Clinical Research

    Atlanta, Georgia · Recruiting

  • Nephrology Associates of Northern Illinois and Indiana (NANI)

    Hinsdale, Illinois · Recruiting

  • Dunes Clinical Research

    Dakota Dunes, South Dakota · Recruiting

  • Prolato Clinical Research Center

    Houston, Texas · Recruiting

  • Clinical Trial Network

    Houston, Texas · Recruiting

  • Clinical Advancement Center

    San Antonio, Texas · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Western Health Sunshine Hospital

    St Albans, Victoria, Australia · Recruiting

  • AIIMS Hospital

    Raipur, Chhattisgarh, India · Active not recruiting

  • Muljibhai Patel Urological Hospital

    Nadiād, Gujarat, India · Active not recruiting

  • Dhiraj Hospital

    Vadodara, Gujarat, India · Active not recruiting

  • MS Ramaiah Medical College and Hospitals

    Bangalore, Karnataka, India · Active not recruiting

  • Mazumdar Shah Medical Center

    Bangalore, Karnataka, India · Active not recruiting

  • Manipal Hospital

    Pune, Maharashtra, India · Active not recruiting

  • MGM Medical Care and Hospital

    Sambhajinagar, Maharashtra, India · Active not recruiting

  • Sir Ganga Ram Hospital

    New Delhi, National Capital Territory of Delhi, India · Active not recruiting

  • Max Super Speciality Hospital

    Patparganj, National Capital Territory of Delhi, India · Active not recruiting

  • SUM Hospital

    Bhubaneswar, Odisha, India · Active not recruiting

  • SMS Medical College and Hospital

    Jaipur, Rajasthan, India · Active not recruiting

  • Osmania General Hospital

    Hyderabad, Telangana, India · Active not recruiting

  • Nizam's Institute of Medical Sciences

    Hyderabad, Telangana, India · Active not recruiting

  • Sanjay Gandhi Post Graduate Institute of Medical Sciences

    Lucknow, Uttar Pradesh, India · Active not recruiting

  • Nutema Hospital

    Meerut, Uttar Pradesh, India · Active not recruiting

  • Shri Guru Ram Rai Institute of Medical and Health Sciences

    Dehradun, Uttarakhand, India · Active not recruiting

  • NRS Medical College and Hospital Kolkata

    Kolkata, West Bengal, India · Active not recruiting

  • Hospital Canselor Tuanku Muhriz UKM

    Cheras, Kuala Lumpur, Malaysia · Recruiting

  • Hospital Kuala Lumpur

    Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting

  • University Malaya Medical Centre

    Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting

  • Hospital Tengku Ampuan Afzan

    Kuantan, Pahang, Malaysia · Recruiting

  • Hospital Sultan Idris Shah Serdang

    Kajang, Selangor, Malaysia · Recruiting

  • Sunway Medical Centre

    Petaling Jaya, Selangor, Malaysia · Recruiting

  • Hallym University Sacred Heart Hospital

    Anyang, South Korea · Recruiting

  • Pusan National University Hospital

    Busan, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea · Recruiting

  • Severance Hospital - Yonsei Cancer Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Soeul, South Korea · Recruiting

  • Ajou University Hospital

    Suwon, South Korea · Recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.